Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Astellas Pharma, Inc. (OTC: ALPMF).

Full DD Report for ALPMF

You must become a subscriber to view this report.


Recent News from (OTC: ALPMF)

Astellas acquires Potenza Therapeutics for up to $405M
Astellas Pharma ( OTCPK:ALPMF ) exercises its exclusive option to acquire immuno-oncology therapy developer Potenza Therapeutics, capping a collaboration agreement that began in 2015. More news on: Astellas Pharma, Inc., Healthcare stocks news, Merger & acquisition news, Read mor...
Source: SeekingAlpha
Date: December, 14 2018 15:33
Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you've followed my news cov...
Source: SeekingAlpha
Date: December, 02 2018 09:58
FDA OKs Astellas' gilteritinib for certain type of leukemia; shares up 2%
The FDA approves Astellas Pharma's ( OTCPK:ALPMF ) Xospata (gilteritinib) for the treatment of adult patients with relapsed/refractory FLT3 mutation-positive acute myeloid leukemia (AML). More news on: Astellas Pharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 28 2018 15:29
Fervent Pharma completes mid-stage study for vasomotor symptoms candidate FP-101
Privately held Fervent Pharmaceuticals announces the completion of a Phase 2a clinical trial evaluating lead candidate FP-101 for the treatment of vasomotor symptoms (e.g., hot flashes, night sweats) associated with menopause. More news on: Dare Bioscience, Inc., TherapeuticsMD, Astell...
Source: SeekingAlpha
Date: November, 14 2018 13:42
Urovant IPO: Phase 3 Clinical Data To Be Released In 2019
Conducting biopharmaceutical research initiated by Merck ( MRK ) and with a massive market opportunity, Urovant ( UROV ) seems an interesting name to be followed once the IPO goes live. With that, the facts that the company was incorporated in Cayman and Roivant Sciences Ltd. controls the comp...
Source: SeekingAlpha
Date: September, 27 2018 11:33
Astellas Pharma, Inc. ADR 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Astellas Pharma, Inc. ADR in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: July, 30 2018 14:47
FDA accepts Astellas' marketing application for gilteritinib for AML
The FDA accepts under Priority Review  Astellas Pharma's ( OTCPK:ALPMF )( OTCPK:ALPMY ) marketing application seeking approval for gilteritinib for the treatment of adult patients with relapsed/refractory FLT3-positive acute myeloid leukemia (AML). The agency's action date is November ...
Source: SeekingAlpha
Date: May, 29 2018 09:17
Astellas Pharma (ALPMY) Presents Strategic Plan 2018 - Slideshow
The following slide deck was published by Astellas Pharma, Inc. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 22 2018 14:19
First Eagle Global Value Team Quarterly Commentary Q1 2018
Read more ...
Source: SeekingAlpha
Date: May, 03 2018 03:02
FDA accepts Pfizer's marketing application for expanded use of Xtandi
Pfizer (NYSE: PFE ) and collaboration partner Astellas Pharma ( OTCPK:ALPMF ) announce that the FDA has accepted under Priority Review the former's marketing application seeking approval for XTANDI (enzalutamide) for the treatment of men with non-metastatic castration-resistant prostate ca...
Source: SeekingAlpha
Date: March, 19 2018 16:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A14.52N/AN/A0
2018-12-1314.5214.5214.5214.52460
2018-12-12N/A14.535N/AN/A600
2018-12-11N/A14.535N/AN/A0
2018-12-10N/A14.535N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0610028634.9650Cover
2018-12-04200200100.0000Short
2018-11-1570070199.8573Short
2018-10-17250250100.0000Short
2018-10-161502,3506.3830Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALPMF.


About Astellas Pharma, Inc. (OTC: ALPMF)

Logo for Astellas Pharma, Inc. (OTC: ALPMF)

Not available

 

Contact Information

 

 

Current Management

  • Masao Yoshida / CEO, President

Current Share Structure

  • Market Cap: $7,206,654,840 - 05/11/2018
  • Issue and Outstanding: 467,964,600 - 11/30/2011

 


Recent Filings from (OTC: ALPMF)

Filing to become effective immediately upon filing
Filing Type: F-6EFFiling Source: edgar
Filing Date: December, 21 2017
Post-effective amendment to a previously filed F-6
Filing Type: F-6 POSFiling Source: edgar
Filing Date: September, 29 2017

 

 


Daily Technical Chart for (OTC: ALPMF)

Daily Technical Chart for (OTC: ALPMF)


Stay tuned for daily updates and more on (OTC: ALPMF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ALPMF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALPMF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALPMF and does not buy, sell, or trade any shares of ALPMF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/